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Amyotrophic lateral sclerosis (ALS) is an incurable neuromuscular disease that leads to a profound loss of life
qualityandprematuredeath.Around10%ofthecasesareinheritedandALS8isanautosomaldominantformof
familial ALS caused by mutations in the vamp-associated protein B/C (VAPB) gene. The VAPB protein is
involved in many cellular processes and it likely contributes to the pathogenesis of other forms of ALS besides
ALS8.AnumberofsuccessfuldrugtestsinALSanimalmodelscouldnotbetranslatedtohumansunderscoring
the need for novel approaches. The induced pluripotent stem cells (iPSC) technology brings new hope, since it
canbeusedtomodelandinvestigatediseasesinvitro.HerewepresentanadditionaltooltostudyALSbasedon
ALS8-iPSC.FibroblastsfromALS8patientsandtheirnon-carriersiblingsweresuccessfullyreprogrammedtoa
pluripotent state and differentiated into motor neurons. We show for the ﬁrst time that VAPB protein levels are
reduced in ALS8-derived motor neurons but, in contrast to over-expression systems, cytoplasmic aggregates
couldnot be identiﬁed.Ourresults suggestthatoptimallevels ofVAPBmay play acentral role inthepathogen-
esis of ALS8, in agreement with the observed reduction of VAPB in sporadic ALS.
INTRODUCTION
Amyotrophiclateralsclerosis(ALS),alsoknownasLouGehrig’s
disease, is the most common adult-onset motor neuron disease
(MND)(1).Clinicalﬁndingsincludemuscularatrophyandweak-
ness, accompanied by fasciculation and spasticity, and a rapid
and progressive degeneration of motor neurons in the cortex,
brainstem and spinal cord (2). Patient’s death occurs between 2
and 5 years after the symptom onset, usually due to respiratory
failure(3).Notonlythereisnocureforthedisease,butitspatho-
genesisisalsopoorlyunderstood.Approximately90%ofallALS
cases are sporadic (SALS) and the remaining 10% comprise the
familial forms (FALS), most having an autosomal dominant
p a t t e r no fi n h e r i t a n c e( 4). More than 10 different loci have
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(SOD1, ALS1) (5), Tar-DNA-binding protein-43 (TDP-43,
ALS10) (6–8), fused sarcoma (FUS, ALS6) (9,10)a n d
vamp-associated protein B/C (VAPB, ALS8) (11).
ALS8 is an autosomal dominant type of FALS that was
ﬁrst mapped in a Brazilian family (12). Subsequently, the
mutation c.166C.T in the vesicle-associated membrane
protein-associated protein-B/C (VAPB/C) gene was identiﬁed
in the original family and six additional ALS pedigrees in
Brazil (11). The pyrimidine transition leads to a substitution
of a proline by a serine at position 56 (P56S) of the VAPB
protein (11). A founder effect is suggested in the Brazilian
families, since they share the same haplotype (13). However,
ALS8 is not restricted to South America. The same P56S
mutation was identiﬁed in Germany (14) and in a patient with
Japaneseancestry(15).TheGermanpatientharborsahaplotype
that is different from the Brazilian families, suggesting that this
P56S mutation arose independently from the Brazilian founder
mutation (14). Additionally, a recent study found a new
mutation(T46I) inaBritishALS patient leading tosimilar mol-
eculardefectsastheP56Salteration(16).Thesemutationshave
not been observed in persons who are not affected by ALS or
other MNDs (11,16). Together, these data provide evidence
that ALS8 is not as rare as previously proposed (17,18).
ALS8 is associated with a highly variable clinical course.
Some affected patients may have a rapid and severe course,
while others exhibit a slow progression, and it sometimes
takes decades before a severe motor disability develops (11
and unpublished data). Understanding what protects some indi-
viduals from the deleterious effect of the VAPB mutation is of
great interest since it may provide a window for treatments.
VAPB is a type II integral membrane protein comprised of
an amino terminal major sperm protein (MSP), a central coiled-
coil and an endoplasmatic reticulum membrane anchored
carboxy terminal domain (19–21). This protein is phylogeneti-
cally well conserved; homologs of VAPB are found across
species from yeast to mammals (11,21,22). VAPs are typically
ubiquitously expressed and localized to the endoplasmic reti-
culum and pre-Golgi intermediates (23). They have been impli-
cated in numerous cellular functions, including the regulation
of lipid transport and homeostasis, formation of presynaptic
terminal and unfolded protein responses (UPRs) (24). VAP
was also shown to function as a secreted hormone as the
MSP domain of VAP is cleaved, secreted and act as a ligand
for Eph receptor in worms and ﬂies (25). Hence, defects in
many cellular processes are likely to be involved in the patho-
genesis of ALS8. The biological nature of the P56S mutation
seems complex. First, the P56S mutation may cause a loss of
function as it leads to a reduced level of interaction of VAPB
with some key proteins (26). However, mild over-expression
of the mutant VAPB has been shown to induce an UPR in cul-
tured cells (27) and ﬂies (25),similar towhat has been observed
in SOD1 mice (28). These data indicate that it may be toxic,
and have gain of function properties. Finally, the mutation
may also cause a dominant negative effect since the mutant
protein sequesters wild-type (WT) VAPB, contributing to cyto-
plasmic aggregates (16,21).
Loss of VAPB function may contribute to other familial and
sporadic ALS. Indeed, a reduction in VAPB protein levels has
been documented in motor neurons from SALS patients
(29,30). Moreover, VAPB levels decrease concomitantly
with disease’s progression in the SOD1 mouse model (29).
However, it has not been determined how loss of VAPB is
involved in the pathogenesis of sporadic or familial ALS.
The study of ALS in human cells may help establish how
the loss of VAPB causes the disease but such cells are cur-
rently not available. The induced pluripotent stem cell
(iPSC) technology provides a new opportunity as it allows
ALS patients’ genomes to be captured in pluripotent stem
cell lineages. Creating iPSC from tissues from ALS patients
may also address human-speciﬁc effects maintaining the
genetic background in which the disease occurs (31). Here,
we demonstrate the successful generation of iPSC and
further motor neuron differentiation from ALS8 patient cells.
We ﬁnd that the VAPB protein is present in pluripotent stem
cells and motor neurons derived from iPSCs. Importantly,
we show that the levels of VAPB are reduced in ﬁbroblasts,
in iPSCs and motor neurons of ALS8 patients. We propose
that reduced levels of VAPB might be an initial defect
leading to ALS8 pathogenesis and that ALS8-iPSC could be
used to develop early diagnostic tools and to identify possible
drugs and targets for future therapies.
RESULTS
Generation of iPSCs from ﬁbroblasts of ALS8 patients
In order to reduce possible differences caused by the genetic
background, we chose two ALS8 families and collected skin
biopsies from affected patients and their non-carrier siblings,
after signing the consent form. Family 1 consists of two non-
affected controls and two patients; and Family 2 has one
control and two patients (Fig. 1A). We cultured the explants
following standard cell culture protocols. We performed cellu-
lar reprogramming as described (32), using c-Myc, Oct3/4,
Klf4 and SOX2 (31). This allowed the generation of human
embryonic stem cell (hESC)-like cells 10–15 days after
virus transduction (Fig. 1B and C). We selected iPSC colonies
based on hESC-like morphology and transferred them to
feeder-free culture conditions (Fig. 1D and E). We success-
fully reprogrammed all seven samples (four patients and
three controls) to iPSCs and expanded them through several
passages. We analyzed the C.T166 mutation using polymer-
ase chain reaction (PCR) and HaeIII restriction enzyme
digests that reveal an unique band for the ALS8 mutation,
not present in control DNA and conﬁrmed the P56S mutation
in all patients derived cells (Supplementary Material, Fig. S1).
To determine whether the cells are pluripotent, we carried out
immunocytochemistry of iPSC colonies with pluripotent
markers. We found that iPSC from control individuals and
ALS8 patients expressed both Lin28 and Nanog (Fig. 1F–I).
We also performed semi-quantitative RT–PCR using
primers for the endogenous expression of Oct4 and Nanog
to examine their expression. We found that these markers
are present in iPSC but not in ﬁbroblasts from the same indi-
vidual (Supplementary Material, Fig. S2). More importantly,
to conﬁrm if induced iPSCs have pluripotency in vivo,w e
injected them subcutaneously in nude mice to examine
whether the iPSCs can induce teratomas. Indeed, we found
tissues derived from the three germ layers, including gut-like
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mesodermal and neural rosettes from ectodermal origin
(Fig. 1J–M). To ensure that genomic rearrangements were
not induced, we karyotyped the cells. iPSC chromosomal
number and organization were normal (Fig. 1N–O). These
data collectively suggest that we successfully generated
ALS8-iPSCs derived from tissues of ALS8 patients and their
normal siblings.
Next, we examined whether WT or ALS8 mutant VAPB is
expressed in iPSC cells. Although VAPB is shown to be
expressed in many tissues (27), it remains to be established
whether it is expressed in pluripotent cells. To detect the
VAPB protein speciﬁcally, we raised a monoclonal antibody
(A1315F3G10) against a sequence in the VAPB N-terminal
portion. The sequence is unique for VAPB and the antibody
does not recognize the VAPA protein (Supplementary
Material, Fig. S3). We conﬁrmed that the monoclonal VAPB
antibody can detect expression of WT VAPB and mutant
ALS8 in cultured cells expressing WT VAPB and P56S
mutant VAPB, respectively (Fig. 2A). Moreover, this antibody
is able to detect the cytoplasmic inclusions generated by over-
expression of P56S-VAPB (Fig. 2A and inset). We performed
immunostaining of ALS8-iPSCs and control iPSCs with
anti-VAPB antibody and a pluripotent marker, anti-Nanog
antibody. We found that VAPB is expressed in ALS8-iPSCs
similar to control iPSCs (Fig. 2B). Cell reprogramming to a
pluripotent state requires several steps involving transcrip-
tional and epigenetic factors. To further establish that the
VAPB protein is expressed in pluripotent stages, we also
examined the expression of VAPB in human ES cells lines,
HUES9 and HUES6, by western blotting with anti-VAPB anti-
body. We found that VAPB is also expressed in both human
ES cells (Fig. 2C), suggesting that it is present in cells at plur-
ipotent stages. Taken together, the data indicate that the P56S
mutation in iPSCs does not interfere with pluripotency.
P56S VAPB mutation does not inhibit differentiation
and maintenance of motor neuron derived from iPSC
To determine whether the motor neurons of ALS8 patients
derived from iPSCs display defects, we induced motor
neuron differentiation from ALS8-iPSCs and controls based
on a previous protocol (33) with minor modiﬁcations (see
Materials and Methods). To identify motor neurons, we
Figure 1. Generation and characterization of controls and ALS8-patients iPSCs. (A) Heredograms of the two studied ALS8 families. ALS8 patients are rep-
resented in dark symbols and non-affected individuals in white. Skin biopsies were collected (∗) from two affected and two control individuals of family 1;
and one control and two affected individuals of family 2. (B) Phase contrast showing iPSC colony morphology after 1 week post-infection growing in mitotically
inactivated mouse embryonic ﬁbroblasts. (C) Isolated iPSC colony with similar morphology to hESCs. (D) iPSC colony on feeder-free condition. (E) Repre-
sentative image of an established human iPSC colony, with well-deﬁned borders and compact cells. Bar ¼ 100 mm. ALS8-iPSC (F and G) and WT-iPSC
(H and I) staining, showing the expression of pluripotent markers. Bar ¼ 20 mm. Derived iPSC clones were able to generate teratomas in nude mice.
Tissues from the three germ layers could be identiﬁed, as shown by arrows: mesoderm: cartilage (J) and muscle (L); endoderm: gut-like epithelium (K); ecto-
derm: neural rosettes (M). Bar ¼ 200 mm. The karyotype from ALS8- (N) and WT-iPSCs (O) showed normal chromosomal number.
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(Hb9::GFP) (33). We ﬁrst created embryoid bodies (EBs) in
suspension and induced neuronal cells from iPSCs. After 4
weeks of incubation, we conﬁrmed neuronal differentiation
by the expression of motor neuron progenitor marker Islet-1
(Fig. 3A) and the postmitotic neuronal marker Map2
(Fig. 3B and C). We then dissociated EBs and plated them
on coated dishes. After 7 weeks of differentiation, we
observed expression of the HB9::GFP reporter, in both
control and ALS8-iPSC-derived cells, suggesting the induc-
tion of motor neurons from both ALS8-iPSCs and control
iPSCs (D). Finally, iPSC-derived motor neurons were
co-cultured with C2C12 myoblasts and could incorporate
a-bungarotoxin, revealing neuromuscular junction formation
(Fig. 3E and F). Under these conditions, ALS8-iPSCs could
be differentiated into motor neurons with similar efﬁciency
as control-iPSCs,  5%, suggesting that P56S mutant VAPB
does not inhibit motor neuron differentiation and maintenance
(Supplementary Material, Fig. S4).
ALS8 mutation does not cause cytoplasmic inclusions
in iPSC-derived motor neurons
Abnormal inclusion of cellular proteins is a common feature
of many neurodegenerative diseases. Similarly, cytoplasmic
inclusions of ALS8 mutant VAPB are likely to be a key patho-
logical feature of ALS8. In cultured cells (11,29,34–38), ﬂies
(21,25,39) and mice (40), expression of mutant VAPB causes
cytoplasmic inclusions, which also recruit the WT form into
the inclusions (25,29). To determine whether VAPB protein
inclusions are early pathological features in ALS8 patients,
we performed immunostaining of motor neurons derived
from control and ALS8-iPSCs. We used motor neurons
maintained for 7 weeks of differentiation. VAPB is expressed
diffusely in the cytoplasm of motor neurons derived from
ALS8-iPSCs similar to control motor neurons (Fig. 3G and
H). In contrast to cells expressing mutant VAPB at high
levels (Fig. 2A), we did not observe cytoplasmic inclusions
of the VAPB protein in motor neurons.
Figure 2. VAPB in human cells. (A) Over-expression of WT and P56S forms of VAPB in HEK293T cells. Controls in this experiment were the non-transfected
HEK293T cells. While the WT form showed a cytoplasmic distribution with higher intensity around the nucleus, over-expression of mutant protein was mainly
localized as cytoplasmic aggregates. Bar ¼ 70 mm. Inset: detail of cytoplasmic inclusions generated by P56S-VAPB over-expression on HEK293T cells.
(B) VAPB shows perinuclear staining on both WT and ALS8-iPSC expressing the pluripotent marker Nanog. Bar ¼ 50 mm. (C) hESCs also express VAPB.
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nated (21,34), and ubiquitinated VAP typically accumulates in
cytoplasmic inclusions (21). We therefore asked whether
increasing levels of VAPB by disturbing the ubiquitin/protea-
some system might enhance ubiquitinated VAPB and cyto-
plasmic aggregates that would not appear under normal cell
culture conditions. The proteasome system can be inhibited by
the use of a proteasome inhibitor, MG132 (41). We examined
ubiquitinated proteins and VAPB inclusions in the presence of
MG132 in ﬁbroblasts and motor neurons derived from control
and ALS8-iPSCs. In the presence of MG132, we detected an
increase in ubiquitin staining in ﬁbroblasts and motor neurons,
indicating a successful inhibition of proteasome function
(Fig. 4). However, we did not observe an increased accumu-
lationofubiquitinatedproteininALS8-treatedﬁbroblasts,com-
paredwithcontrolcells(Fig.4A).Similarly,wedidnotobserve
increased accumulation of ubiquitinated protein in differen-
tiated motor neurons submitted to MG132 treatment, compared
withcontrolcells(Fig.4B).Surprisingly,bothcontrolandALS8
ﬁbroblasts show reduced VAPB levels after MG132 treatment,
suggestingthatproteinregulatorysystemsotherthantheprotea-
some are acting over VAPB pathway (Fig. 4C).
Figure 3. Motor neuron differentiation. (A) Expression of the motor neuron progenitor Islet-1 marker in neuroectodermal cells after 4 weeks of differentiation as
EB. Bar ¼ 12 mm. (B) A mature EB section revealing robust neuronal differentiation, presented by the presence of cells expressing the postmitotic neuronal
marker Map2. Bar ¼ 10 mm. (C) Cells expressing the mature neuronal marker Map2 also express TDP-43 in the nucleus (inset). Bar ¼ 20 mm. (D) Live
image of motor neuron-like cells expressing GFP under the control of the Hb9 promoter. Bar ¼ 100 mm. (E) Control and (F) ALS8- iPSC-derived motor
neurons can incorporate a-bungarotoxin at neuromuscular junctions when co-cultured with C2C12 myoblasts. (G) Perinuclear VAPB distribution on a
GFP-positive motor neuron derived from a control iPSC clone and (H) from an ALS8. Bar ¼ 20 mm.
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neuron induction
We sought to determine whether the levels of VAPB protein in
ALS8-iPSCs and motor neurons differ in patients when com-
pared with controls. Interestingly, there is a reduction in the
levels of VAPB protein in ALS8-iPSCs when compared
with control iPSCs (Fig. 5A and B). The reduction in VAPB
protein levels is consistently observed independent of the
iPSC clone used for comparison (Supplementary Material,
Fig. S5). We then examined whether the decreased levels of
VAPB protein are also observed during induction of motor
neurons. We performed immunoblotting analysis and com-
pared VAPB levels in control and ALS8-iPSC-derived
lineages. As shown in Figure 5C and D, in all stages of differ-
entiation, VAPB is signiﬁcantly reduced in cells derived from
Figure 4. VAPB staining after MG132 treatment. (A) Fibroblasts treated with MG132 increased the number of ubiquitin puncta staining (arrows). Bar ¼ 25 mm.
(B) VAPB perinuclear distribution is similar between control and ALS8-iPSCs-derived Hb9::GFP motor neurons after MG132 treatment. Bar ¼ 10 mm.
(C) Representative data of a western blot for VAPB protein stability after dimethyl sufoxide or MG132 treatment. Higher ubiquitin staining in MG132 lanes
shows that proteasome was inhibited. (D) Graph represents the average of VAPB protein amount after treatment from two individual controls and two
ALS8 patients from the two families.
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ally increase during the differentiation process of control
iPSCs (Fig. 5D). However, we did not observe the upregula-
tion of VAPB protein during neuronal differentiation of
ALS8-iPSCs (Fig. 5D), suggesting that the ALS8 mutation
causes a failure of upregulation of VAPB protein during neur-
onal and motor neuron inductions. To determine whether the
amount of VAPB protein is controlled at the transcriptional
level, we performed a real-time PCR analysis. VAPB
mRNA levels do not differ between control and ALS8 ﬁbro-
blast cultures, suggesting that the VAPB regulation is likely
to happen at the post-translational level (Supplementary
Material, Fig. S6).
DISCUSSION
ALS is a fatal condition whose pathogenesis is still poorly
understood. The generation of familial ALS mouse models,
especially SOD1, has helped clarify several important
aspects of the disease pathogenesis, but a precise molecular
mechanism is still lacking. Importantly, several drug tests
that were somewhat successful in animal systems were not
successfully translated into humans (42). The lack of success
of translating these strategies in ALS patients may be due to
the use of a single animal model, namely SOD1 mice that
carry a high transgene copy number (42,43). Hence, there is
a need to create other mouse models as well as strategies to
test drugs. The ALS8-associated neurodegeneration pathway
seems to share common traits with other ALS forms (29)
and the observation that the VAPB protein levels are
decreased in sporadic patients so far suggests that it may
play an important role in the pathogenesis of numerous
forms of the disease (29,30). Thus, we decided to produce
ALS8 patient-derived iPSCs as well as iPSCs from their
non-carrier siblings as controls.
All ﬁbroblast samples were reprogrammed to a pluripotent
status. Their cellular and molecular characterization docu-
ments that these are bona ﬁde iPSC. We found no obvious
alterations in the VAPB distribution pattern of control and
ALS8 cells, and it was not possible to identify inclusions in
ALS8-derived motor neurons even after the 7–8 weeks
required for neuronal maturation. In addition, the use of the
proteasome inhibitor MG132 did not exacerbate the lack of
aggregation. This failure to detect aggregates extended to all
cell types—ﬁbroblasts, iPSC and cells induced to differentiate
into motor neuron. It is important to note that transgenic
mutant VAPB mice do not develop MND, although cyto-
plasmic inclusions appear when they are  18 months old
(40). It is possible that the short longevity of the motor
neurons in vitro may not permit detection of aggregates in
our system. Intracytoplasmic aggregates are found in many
different forms of ALS, including SOD1 (ALS1) (44,45),
TDP-43 (ALS10) (6–8), FUS/TLS (ALS6) (9) and VAPB
itself (11,21,25,29,34–40). Many of the aggregates are also
immunopositive for TDP-43. However, they are not found in
SOD1 models (46) nor have they been documented in trans-
genic mice carrying the A315T mutation of the TDP-43
protein (47). Hence, it is not obvious how these aggregates
relate to the pathogenesis. It is possible that the neurotoxicity
is not due to cytoplasmic inclusions itself (47).
We showed that VAPB is expressed early in development in
pluripotent stem cells and that the protein levels increase
during motor neuron differentiation. Similar to other studies
(48,49), our results suggest that mutations that cause MNDs
are unlikely to affect cell reprogramming. This even seems
to be the case when the affected protein is expressed in plur-
ipotent stages, as for VAPB (this work) and the SMN
protein, responsible for spinal muscular atrophy (48). The
importance of VAPB levels has been documented in
Drosophila neuromuscular junctions. Over-expression of the
VAPB orthologue, dVAP-33, in ﬂies reduces the size of
boutons at neuromuscular junctions and increases their
number, while a reduction or loss of dVAP33 causes a
reduction in number and an increase in bouton size (50).
The signiﬁcant reduction in VAPB protein levels especially
in motor neurons of ALS8 patients compared with their non-
carrier siblings may therefore have biological consequences.
The reduction in VAPB is .50% in ALS8 cells when com-
pared with controls. Since VAPB transcript amounts are
very similar between control and ALS8 patients’ samples,
we propose that its expression is regulated at the protein
level. The reduction in the VAPB protein after MG132 treat-
ment is in agreement with the absence of aggregates in
immunocytochemistry. Accordingly, blocking the ubiquitin
pathway did not rescue VAPB levels. Once VAPB reduction
is also observed in ﬁbroblasts, these cells could become an
alternative source to evaluate strategies aiming the correction
of the VAPB’s mutant phenotype. There are several possible
explanations for VAPB protein reduction in ALS8 patients.
The mutant protein may not be properly folded and is less
Figure 5. Reduction in VAPB protein levels in ALS8-derived motor neurons.
(A and B) VAPB levels on iPSC lines are reduced on ALS8 samples when
compared with controls (Con). (C) Reduced levels of VAPB in ALS8 cells
during differentiation. (D) VAPB increases during motor neuron differen-
tiation of control but not from ALS8-iPSC. n ¼ 3 independent experiments.
3648 Human Molecular Genetics, 2011, Vol. 20, No. 18stable (51,52). Alternatively, it may be that the mutant chain
forms a dimer with the wild-type isoforms (38,53), destabiliz-
ing the wild-type protein as well. This would imply that the
ALS8 mutation functions as a dominant negative allele, and
should share features with null alleles, as previously documen-
ted (36). Additionally, expression of P56SVAPB shows
similar effects as of VAP knockdown on primary neurons,
since both induce cell death (29). Results from our work and
others (29,36) support the hypothesis that P56S dominant
effect is, at least in part, due to VAPB loss of function.
The reduction in VAPB ratio levels between patients and
controls enforces the idea that iPSC technology can recapitu-
late the patients’ original cell status (32,54,55). The fact that
VAPB is reduced in motor neurons from ALS8 patient’s
samples suggests that the correct amount of VAPB may be
crucial for their survival. The decreased VAPB protein
levels in sporadic ALS postmortem tissue and the concomitant
reduction in this protein with ALS progression in SOD1
mutant mice strengthen this hypothesis (29). Interestingly,
concomitantly with neuronal differentiation, WT cultured
cells present an increment of VAPB levels not observed in
the mutant cultures. It is known that VAPB processing is
different in certain brain regions and during development
(27,53). We hypothesize that, even in the presence of a
smaller amount of VAPB, ALS8 carriers are normal until
they reach the fourth or ﬁfth decade of life, when the levels
become critically low. Our results indicate that the iPSCs
can recapitulate some aspects of ALS8 and be used to
extract new biological information relevant to human motor
neuron development. We believe this cellular model has the
potential to complement other human and animal models to
accelerate the discovery of new compounds for treating ALS
and other forms of motor neuron neurodegeneration.
MATERIALS AND METHODS
Skin biopsy
All procedures were conducted with the approval of commit-
tees from University of Sa ˜o Paulo (USP, Brazil), Federal
University of Sa ˜o Paulo (UNIFESP, Brazil) and University
of California San Diego (UCSD). ALS8 patients were ana-
lyzed by experienced neurologists that deﬁned the diseases
based on clinical ﬁndings. Initially, DNA was extracted from
lymphocytes. The mutation c.C.T166 (P56S) was conﬁrmed
by HaeIII enzyme digestion and by the sequencing of the
amplicon containing the exon 2 (11). ALS8 families were
selected according to the availability to meet the criteria of a
minimum of two affected and one normal sibling from the
same genitors. Skin biopsies were performed by a neurologist,
using a 3 mm punch, after local anesthesia. Explants were
collected in Dulbecco’s modiﬁed eagle medium (DMEM)
(1×) with 5% (v/v) antibiotics (Pen/Strep 10 000 U/ml).
Fibroblast cell culture was implemented using DMEM (1×)
with 10% (v/v) fetal bovine serum and 2% (v/v) antibiotics.
Cellular reprogramming
Cellular reprogramming was performed as previously
described (32). Brieﬂy, the four Yamanaka factors (c-Myc,
Oct3/4, Klf4 and SOX2)( 31) in a retrovirus system were
used to infect ﬁbroblasts at low passage. After 2 days, infected
human ﬁbroblasts were moved to hESC conditions on a feeder
layer of irradiated mouse embryonic ﬁbroblasts (Chemicon).
hESC-like cells appear 10–15 days after virus transduction.
iPSC colonies were selected by morphology and manually
moved to a feeder-free condition in Matrigel-coated dishes
(BD Bioscience) and mTeSR1 (Stem Cell Techonologies).
iPSCs were manually passed and maintained on feeder-free
condition until the beginning of the differentiation protocol.
Three clones from one control and from two patients were
selected for further characterization for each family.
Teratoma formation
Approximately 3 × 10
6 iPSCs were injected subcutaneously
into the dorsal ﬂanks of nude mice (CByJ.Cg-Foxn1 nu/J)
anesthetized with isoﬂurane. Five to 6 weeks after injection,
teratomas were dissected, ﬁxed overnight in 10% formalin
phosphate and embedded in parafﬁn. Sections were stained
with hematoxylin and eosin for further analysis. Protocols
were previously approved by the University of California
San Diego Institutional Animal Care and Use Committee.
Motor neuron differentiation
Motor neuron differentiation was based on previous protocol
(33) with some modiﬁcations. Brieﬂy, the differentiation com-
prised a period of 7–8 weeks, with 5% efﬁciency at the end
from both control and patients’ samples. Conﬂuent iPSC on
feeder-free condition was moved to N2 media on F12/
DMEM (Invitrogen, Carlsbad, CA, USA), on day 0. On the
following day, a BMP signaling inhibitor, dorsomorphin—
1 mM (Calbiochem), was added. On the third day, colonies
were dissociated using dispase (0.5 mg/ml) and kept under
rotation at 378C to form EBs. Cells were maintained in this
condition for 4 more weeks with the gradual addition of neur-
onal survival and differentiation inducers as follows: day 9,
addition of differentiation retinoic acid (1 mM) and ascorbic
acid (200 ng/ml) were added; day 16, addition of sonic hedge-
hog (SHH—500 ng/ml: R&D Systems), brain-derived neural
factor (20 ng/ml: Peprotech), growth-derived neural factor
(20 ng/ml: Peprotech) with the simultaneous dorsomophin
removal. On day 30, cells were plated on poli-ornitine/
laminin-coated plates and kept in culture for additional 3–4
weeks. After cell platting, the previous neural induction
media were modiﬁed by the reduction of SHH to 100 ng/ml
and addition of cyclic adenosine monophosphate (1 mM).
Hb9::GFP reporter construct was transferred to the cells
using a lentivirus system (33). The lentivirus was added to
the culture either at the dissociation moment or 2 days after
plating the cells on poli-O/L. For neuromuscular junction
assays, we used C2C12 myoblasts (ATCC) as previously
described (33). Brieﬂy, motor neuron progenitors were
plated on top of the myotubes for  4 weeks. Cells were
ﬁxed, and the formation of neuromuscular junctions detected
by incorporation of a-bungarotoxin conjugated with Alexa
568 (1:200, Molecular Probes, Invitrogen).
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MG132 (Sigma) was used to block the proteasome system.
Several attempts were made to optimize the MG132 concen-
trations. Fibroblasts were kept for 24 h with 10 mM of
MG132. Motor neurons were treated with 5 mM of the inhibitor
for 24 h.
Karyotyping
Standard G-banding chromosome analysis was performed
by Cell Line Genetics (Madison, WI, USA) and Molecular
Diagnostic Services, Inc (San Diego, CA, USA).
Immunocytochemistry
Cells were ﬁxed with 4% paraformaldehyde, followed by per-
meabilization and blocking with 0.1% (v/v) Triton X in PBS
containing 5% (v/v) donkey serum, for 1 h. Primary antibodies
were incubated overnight at 48C. Samples were washed three
times before secondary antibodies incubation (Jackson Lab-
oratories and Alexa Fluor Dyes, Life Technologies) for 1 h.
Primary antibody concentrations were: a-hVAPB mouse
monoclonal A1315F3G10 1:500; a-ubiquitin rabbit polyclonal
1:1000 (Dako); a-nanog mouse monoclonal 1:100 (BD Bio-
science); a-Oct3/4 mouse monoclonal 1:250 (Santa Cruz);
a-Lin28 goat polyclonal 1:400 (R&D Systems); a-MAP2
mouse polyclonal 1:200 (Milipore); a-TDP-43 rabbit polyclo-
nal 1:500 (Novus Biologicals); a-GFP chicken polyclonal
1:500 (Aves Lab) and a-ChAt 1:100 (Chemicon). Images
were obtained trough Olympus FV1000 confocal microscope
and Zeiss immunoﬂuorescence microscope.
Western blot analysis
Cells were collected, re-suspended in 1× RIPA lyses buffer
(Milipore) containing 1% (v/v) protein inhibitor cocktail
(Sigma), triturated and centrifuged at 10 000g for 20 min at
48C. Ten micrograms of protein extract were separated in a
4–12% pre-cast Bis–Tris acrylamide gradient gel (Invitrogen,
Life Tech), transferred to a nitrocellulose membrane and
probed with primary antibodies: a-hVAPB mouse monoclonal
A1315F3G10 1:1000, or a-ubiquitin rabbit polyclonal 1:1000
(Dako), followed by horseradish peroxidase-conjugated sec-
ondary antibody. Visualization was made by ECL chemilumi-
nescence (Amersham). Membranes were striped and re-probed
using antibodies against b-actin 1:5000 (Ambion) and tubulin
1:5000 (Ambion) to generate a control for protein loading. For
semi-quantitative analysis, ﬁlms were scanned with Typhoon
8600 scanner (Molecular Dynamics) and band signal intensity
was analyzed and corrected with respect to tubulin and b-actin
using ImageJ.
RNA extraction and RT–PCR
Total RNA was extracted using Trizol. Reverse transcriptase
reaction was performed by the use of Super Script III First-
Strand Synthesis System for RT–PCR from Invitrogen.
cDNA synthesis was ampliﬁed by PCR using the following
primers: Nanog F 5′-cctatgcctgtgatttgtgg-3′ and Nanog R
5′-ctgggaccttgtcttccttt-3′;h Oct4 F 5′-gggaggggaggagctagg-3′
and hOct4 R 5′-tccaaccagttgccccaaac-3′. We performed real-
time PCR with SYBR Green Mix and using primers for
GAPDH F 5′-TGCACCACCAACTGCTTAGC-3′ and R 5′-gg
catggactgtggtcatg-3′; VAPB F 5′-ccaatagtgtctaagtctctgag-3′
and R 5′-gtccatcttcttccttgaactg-3′ on 7500 Real-Time PCR
System (Applied Biosystems/Life Tech). Results were
extracted and analyzed using 7500 Software v2.0.4.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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